Testing multiple primary endpoints in clinical trials with sample size adaptation
- PMID: 26607410
- DOI: 10.1002/pst.1724
Testing multiple primary endpoints in clinical trials with sample size adaptation
Abstract
In this paper, we propose a design that uses a short-term endpoint for accelerated approval at interim analysis and a long-term endpoint for full approval at final analysis with sample size adaptation based on the long-term endpoint. Two sample size adaptation rules are compared: an adaptation rule to maintain the conditional power at a prespecified level and a step function type adaptation rule to better address the bias issue. Three testing procedures are proposed: alpha splitting between the two endpoints; alpha exhaustive between the endpoints; and alpha exhaustive with improved critical value based on correlation. Family-wise error rate is proved to be strongly controlled for the two endpoints, sample size adaptation, and two analysis time points with the proposed designs. We show that using alpha exhaustive designs greatly improve the power when both endpoints are effective, and the power difference between the two adaptation rules is minimal. The proposed design can be extended to more general settings.
Keywords: family-wise error rate; group sequential design; multiple primary endpoints; sample size adaptation.
Copyright © 2015 John Wiley & Sons, Ltd.
Similar articles
-
Nested combination tests with a time-to-event endpoint using a short-term endpoint for design adaptations.Pharm Stat. 2019 May;18(3):329-350. doi: 10.1002/pst.1926. Epub 2019 Jan 16. Pharm Stat. 2019. PMID: 30652401
-
Design and analysis issues of multiregional clinical trials with different regional primary endpoints.J Biopharm Stat. 2012 Sep;22(5):1051-9. doi: 10.1080/10543406.2012.701586. J Biopharm Stat. 2012. PMID: 22946949 Review.
-
Power and sample size determination in clinical trials with multiple primary continuous correlated endpoints.J Biopharm Stat. 2014;24(2):378-97. doi: 10.1080/10543406.2013.860156. J Biopharm Stat. 2014. PMID: 24605975
-
Statistical considerations for testing multiple endpoints in group sequential or adaptive clinical trials.J Biopharm Stat. 2007;17(6):1201-10. doi: 10.1080/10543400701645405. J Biopharm Stat. 2007. PMID: 18027226
-
Design, data monitoring, and analysis of clinical trials with co-primary endpoints: A review.J Biopharm Stat. 2018;28(1):28-51. doi: 10.1080/10543406.2017.1378668. Epub 2017 Oct 30. J Biopharm Stat. 2018. PMID: 29083951 Free PMC article. Review.
Cited by
-
The Use of Multiple Primary Outcomes in Randomized Controlled Trials of Chinese Herbal Medicine.Evid Based Complement Alternat Med. 2021 Apr 21;2021:9975351. doi: 10.1155/2021/9975351. eCollection 2021. Evid Based Complement Alternat Med. 2021. PMID: 33995551 Free PMC article. Review.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical